Biohaven Pharmaceuticals

News

Four more drugs in keenly watched ALS trial miss the mark

ALS candidates from Biohaven, Prilenia, Clene, and UCB were unable to slow disease progression in the study, but two showed signs of efficacy.

News

Pfizer offers $60m to settle prescriber kickback claims

Pfizer has paid $60m to settle US government allegations that its Biohaven unit made improper payments to prescribers of its migraine drug Nurtec ODT.

News

Scholar Rock preps filings after SMA antibody clears trial

Shares in Scholar Rock have gone into overdrive after the biotech reported positive phase 3 results with apitegromab in patients with spinal muscular atrophy (SMA), setting up regulatory fi

News

Chasing rivals, AbbVie files migraine prevention drug atogep...

AbbVie has submitted its oral CGRP inhibitor atogepant for prevention of both episodic and chronic migraine in the EU as it tries to catch up with main rivals Pfizer/BioHaven and their rece

News

AbbVie files Qulipta for chronic migraine prevention

AbbVie has filed for approval of its oral CGRP inhibitor Qulipta for prevention of chronic migraine, seeking to leap ahead of its main rival in the class.

News